Abstract
Recent work has found increasing evidence of mitigated, incompletely penetrant phenotypes in heterozygous carriers of recessive Mendelian disease variants. We leveraged whole-exome imputation within the full UK Biobank cohort (N∼500K) to extend such analyses to 3,481 rare variants curated from ClinVar and OMIM. Testing these variants for association with 57 quantitative traits yielded 103 significant associations involving variants previously implicated in 35 different diseases. Notable examples included a POR missense variant implicated in Antley-Bixler syndrome that associated with a 1.76 (s.e. 0.27) cm increase in height, and an ABCA3 missense variant implicated in interstitial lung disease that associated with reduced FEV1/FVC ratio. Association analyses with 1,257 disease traits yielded five additional variant-disease associations. We also observed contrasting levels of recessiveness between two more-common, classical Mendelian diseases. Carriers of cystic fibrosis variants exhibited increased risk of several mitigated disease phenotypes, whereas carriers of spinal muscular atrophy alleles showed no evidence of altered phenotypes. Incomplete penetrance of cystic fibrosis carrier phenotypes did not appear to be mediated by common allelic variation on the functional haplotype. Our results show that many disease-associated recessive variants can produce mitigated phenotypes in heterozygous carriers and motivate further work exploring penetrance mechanisms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
A.R.B. was supported by US NIH grant 323 T32 HG229516 and fellowship F31 HL154537. M.L.A.H. was supported by US NIH fellowship F32 324 HL160061. M.A.S. was supported by the MIT John W. Jarve (1978) Seed Fund for Science Innovation 325 and US NIH fellowship F31 MH124393. R.E.M. was supported by US NIH grant K25 HL150334 and 326 NSF grant DMS-1939015. P.-R.L. was supported by US NIH grant DP2 ES030554, a Burroughs 327 Wellcome Fund Career Award at the Scientific Interfaces, the Next Generation Fund at the Broad 328 Institute of MIT and Harvard, and a Sloan Research Fellowship. The funders had no role in study 329 design, data collection and analysis, decision to publish or preparation of the manuscript. 330 Computational analyses were performed on the O2 High Performance Compute Cluster, supported by 331 the Research Computing Group, at Harvard Medical School (http://rc.hms.harvard.edu).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data from the UKB Resource were accessed under application number 10438. All data were collected and made available by the UKB under North West-Haydock Research Ethics Committee reference 16/NW/0274.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Access to the UKB Resource is available by application (http://www.ukbiobank.ac.uk/).
